Manufacturing and Analytical Services
Manufacturing and Analytical Services
Nanomilling from Screening to Scale-up
ISSUE NO. 19 — Hallucinogens, Psychedelics, Entactogens: Challenges Associated With Schedule 1 Therapeutic Development
ISSUE NO. 17 — Maximizing Drug Formulation for First-in-Human Trials
2020 Year in Review
2020 has been quite a year! Each year, we strive to provide you with a more innovative, simplified, and seamless early phase drug development journey. And the past 12 months have been no exception.
Improving Solubility of Molecules via Nanomilling
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Bioavailability ConsiderationsThe formulation of an active pharmaceutical ingredient (API) to ensure maximum bioavailability is central to successful drug development. From Lead Candidate to In-life Use
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
From Lead Candidate to In-life Use – Manufacturing Drugs from Formulation Development to CommercializationPodcast Speakers:Steve Schweibenz, President, Manufactur Utilizing Nano Particulate Formulations in the Delivery of Poorly Soluble Drugs
Altasciences Fills Need of Leading Cancer Therapeutic Drug Developer
|